eTheRNA Announces Relocation and Expansion of R&D Facility to Zwijnaarde Science Park in Gent

GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium.

The upgraded R&D facility is in the Zwijnaarde Science Park, where a cluster of biotech companies are located, and includes state-of-the-art laboratories together with allied services. The increased capacity available will allow eTheRNA’s research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications, resulting in improved control and faster production cycles.

Read more at: News | Archive 2022 | eTheRNA immunotherapies NV


Contact us

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

© Gate Health. All rights reserved. Powered by